Dr. Baltazar Gomez-Mancilla

Associate Professor
Novartis Institute Biological Research, Basel, Switzerland

Highest Degree
Ph.D. in Neurobiology from Laval University, Canada

My URL
https://livedna.org/41.17716

Share this Profile

Area of Interest:

Biomedical Sciences
Neurological Surgery
Stem Cell Biology
Translational Medicine
Psychopharmacology

Selected Publications

  1. Rutrick, D., D.J. Stein, G. Subramanian, B. Smith and M. Fava et al., 2017. Mavoglurant augmentation in OCD patients resistant to selective serotonin reuptake inhibitors: A proof-of-concept, randomized, placebo-controlled, phase 2 study. Adv. Ther., 34: 524-541.
    CrossRef  |  Direct Link  |  

  2. Trenkwalder, C., D. Berg, O. Rascol, K. Eggert and A. Ceballos-Baumann et al., 2016. A placebo-controlled trial of AQW051 in patients with moderate to severe levodopa-induced dyskinesia. Movement Disord., 31: 1049-1054.
    CrossRef  |  Direct Link  |  

  3. Crutcher, E., M. Ali, J. Harrison, J. Sovago, B. Gomez-Mancilla and C.P. Schaaf, 2016. Assessment of cognitive outcome measures in teenagers with 15q13.3 microdeletion syndrome. J. Autism Dev. Disord., 46: 1455-1463.
    CrossRef  |  Direct Link  |  

  4. Brykczynska, U., E. Pecho-Vrieseling, A. Thiemeyer, J. Klein and I. Fruh et al., 2016. CGG repeat-induced FMR1 silencing depends on the expansion size in human iPSCs and neurons carrying unmethylated full mutations. Stem Cell Rep., 7: 1059-1071.
    CrossRef  |  Direct Link  |  

  5. Brasa, S., A. Mueller, S. Jacquemont, F. Hahne and I. Rozenberg et al., 2016. Reciprocal changes in DNA methylation and hydroxymethylation and a broad repressive epigenetic switch characterize FMR1 transcriptional silencing in fragile X syndrome. Clin. Epigenet., Vol. 8. 10.1186/s13148-016-0181-x.
    CrossRef  |  Direct Link  |  

  6. Barch, D.M., S.R. Marder, M.P. Harms, L.F. Jarskog and R.W. Buchanan et al., 2016. Task-related fMRI responses to a nicotinic acetylcholine receptor partial agonist in schizophrenia: A randomized trial. Progr. Neuro-Psychopharmacol. Biol. Psychiatry, 71: 66-75.
    CrossRef  |  Direct Link  |  

  7. Reilmann, R., M.L. Rouzade-Dominguez, C. Saft, S.D. Sussmuth and J. Priller et al., 2015. A randomized, placebo‐controlled trial of AFQ056 for the treatment of chorea in Huntington's disease. Movement Disord., 30: 427-431.
    CrossRef  |  Direct Link  |  

  8. Kaufmann, M., A. Schuffenhauer, I. Fruh, J. Klein and A. Thiemeyer et al., 2015. High-throughput screening using iPSC-derived neuronal progenitors to identify compounds counteracting epigenetic gene silencing in fragile X syndrome. J. Biomol. Screen., 20: 1101-1111.
    CrossRef  |  Direct Link  |  

  9. Gulyas, B., J. Sovago, B. Gomez-Mancilla, Z. Jia and C. Szigeti et al., 2015. Decrease of mGluR5 receptor density goes parallel with changes in enkephalin and substance P immunoreactivity in Huntington's disease: A preliminary investigation in the postmortem human brain. Brain Struct. Funct., 220: 3043-3051.
    CrossRef  |  Direct Link  |  

  10. DeLorenzo, C., J. Sovago, J. Gardus, J. Xu and J. Yang et al., 2015. Characterization of brain mGluR5 binding in a pilot study of late-life major depressive disorder using positron emission tomography and [11C]ABP688. Transl. Psychiatry, Vol. 5. 10.1038/tp.2015.189.
    CrossRef  |  Direct Link  |  

  11. Verpelli, C., I. Galimberti, B. Gomez‐Mancilla and C. Sala, 2014. Molecular basis for prospective pharmacological treatment strategies in intellectual disability syndromes. Dev. Neurobiol., 74: 197-206.
    CrossRef  |  Direct Link  |  

  12. Rascol, O., S. Fox, F. Gasparini, C. Kenney, T. Di Paolo and B. Gomez-Mancilla, 2014. Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias. Parkinsonism Relat. Disord., 20: 947-956.
    CrossRef  |  Direct Link  |  

  13. Pop, A.S., B. Gomez-Mancilla, G. Neri, R. Willemsen and F. Gasparini, 2014. Fragile X syndrome: A preclinical review on metabotropic glutamate receptor 5 (mGluR5) antagonists and drug development. Psychopharmacology, 231: 1217-1226.
    CrossRef  |  Direct Link  |  

  14. Kariuki-Nyuthe, C., B. Gomez-Mancilla and D.J. Stein, 2014. Obsessive compulsive disorder and the glutamatergic system. Curr. Opin. Psychiatry, 27: 32-37.
    CrossRef  |  Direct Link  |  

  15. Jacquemont, S., E. Berry-Kravis, R. Hagerman, F. von Raison and F. Gasparini et al., 2014. The challenges of clinical trials in fragile X syndrome. Psychopharmacology, 231: 1237-1250.
    CrossRef  |  Direct Link  |  

  16. Hagerman, R.J., V. Des-Portes, F. Gasparini, S. Jacquemont and B. Gomez-Mancilla, 2014. Translating molecular advances in fragile X syndrome into therapy: A review. J. Clin. Psychiatry, 75: e294-e307.
    CrossRef  |  PubMed  |  Direct Link  |  

  17. Gomez-Mancilla, B., R. Brand, T.P. Jurgens, H. Gobel and C. Sommer et al., 2014. Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks. Cephalalgia, 34: 103-113.
    CrossRef  |  Direct Link  |  

  18. Gomez-Mancilla, B., E. Berry-Kravis, R. Hagerman, F. von Raison and G. Apostol et al., 2014. Development of mavoglurant and its potential for the treatment of fragile X syndrome. Expert Opin. Invest. Drugs, 23: 125-134.
    CrossRef  |  Direct Link  |  

  19. Di Paolo, T., L. Gregoire, D. Feuerbach, W. Elbast, M. Weiss and B. Gomez-Mancilla, 2014. AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces L-Dopa-induced dyskinesias and extends the duration of L-Dopa effects in Parkinsonian monkeys. Parkinsonism Relat. Disord., 20: 1119-1123.
    CrossRef  |  Direct Link  |  

  20. Morin, N., M. Morissette, L. Gregoire, B. Gomez-Mancilla, F. Gasparini and T. Di Paolo, 2013. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated Parkinsonian monkeys. Neuropharmacology, 73: 216-231.
    CrossRef  |  Direct Link  |  

  21. Morin, N., L. Gregoire, M. Morissette, S. Desrayaud, B. Gomez-Mancilla, F. Gasparini and T. Di Paolo, 2013. MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: Biochemical correlates. Neuropharmacology, 66: 355-364.
    CrossRef  |  Direct Link  |  

  22. Hefti, K., S.C. Holst, J. Sovago, V. Bachmann and A. Buck et al., 2013. Increased metabotropic glutamate receptor subtype 5 availability in human brain after one night without sleep. Biol. Psychiatry, 73: 161-168.
    CrossRef  |  Direct Link  |  

  23. Gasparini, F., T. Di Paolo and B. Gomez-Mancilla, 2013. Metabotropic glutamate receptors for Parkinson's disease therapy. Parkinson's Dis. 10.1155/2013/196028.
    CrossRef  |  Direct Link  |  

  24. Gantois, I., A.S. Pop, C.E. de Esch, R.A. Buijsen and T. Pooters et al., 2013. Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice. Behav. Brain Res., 239: 72-79.
    CrossRef  |  Direct Link  |  

  25. Akkus, F., S.M. Ametamey, V. Treyer, C. Burger and A. Johayem et al., 2013. Marked global reduction in mGluR5 receptor binding in smokers and ex-smokers determined by [11C]ABP688 positron emission tomography. Proc. Natl. Acad. Sci. USA., 110: 737-742.
    CrossRef  |  Direct Link  |  

  26. Tabolacci, E., F. Pirozzi, B. Gomez-Mancilla, F. Gasparini and G. Neri, 2012. The mGluR5 antagonist AFQ056 does not affect methylation and transcription of the mutant FMR1 gene in vitro. BMC Med. Genet., Vol. 13. 10.1186/1471-2350-13-13.
    CrossRef  |  Direct Link  |  

  27. Streffer, J.R., I.D. Grachev, C. Fitzer-Attas, B. Gomez-Mancilla and B. Boroojerdi et al., 2012. Prerequisites to launch neuroprotective trials in Parkinson's disease: An industry perspective. Movement Disord., 27: 651-655.
    CrossRef  |  Direct Link  |  

  28. Sepulveda-Falla, D., J. Matschke, C. Bernreuther, C. Hagel and B. Puig et al., 2011. Deposition of hyperphosphorylated tau in cerebellum of PS1 E280A Alzheimer's disease. Brain Pathol., 21: 452-463.
    CrossRef  |  Direct Link  |  

  29. Ouattara, B., L. Gregoire, M. Morissette, F. Gasparini and I. Vranesic et al., 2011. Metabotropic glutamate receptor type 5 in levodopa-induced motor complications. Neurobiol. Aging, 32: 1286-1295.
    CrossRef  |  Direct Link  |  

  30. Gregoire, L., N. Morin, B. Ouattara, F. Gasparini and G. Bilbe et al., 2011. The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys. Parkinsonism Relat. Disord., 17: 270-276.
    CrossRef  |  Direct Link  |  

  31. Brockmann, K., A. Groger, A. Di Santo, I. Liepelt and C. Schulte et al., 2011. Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers. Movement Disord., 26: 2335-2342.
    CrossRef  |  Direct Link  |  

  32. Berg, D., J. Godau, C. Trenkwalder, K. Eggert and I. Csoti et al., 2011. AFQ056 treatment of levodopa-induced dyskinesias: Results of 2 randomized controlled trials. Movement Disord., 26: 1243-1250.
    CrossRef  |  Direct Link  |  

  33. Ouattara, B., F. Gasparini, M. Morissette, L. Gregoire, P. Samadi, B. Gomez‐Mancilla and T. Di Paolo, 2010. Effect of l‐Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys. J. Neurochem., 113: 715-724.
    CrossRef  |  Direct Link  |  

  34. Ouattara, B., D. Hoyer, L. Gregoire, M. Morissette, F. Gasparini, B. Gomez-Mancilla and T. Di Paolo, 2010. Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias. Neuroscience, 167: 1160-1167.
    CrossRef  |  Direct Link  |  

  35. Morin, N., L. Gregoire, B. Gomez-Mancilla, F. Gasparini and T. Di Paolo, 2010. Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys. Neuropharmacology, 58: 981-986.
    CrossRef  |  Direct Link  |  

  36. Baumann, T.P., H. Duyar, M. Sollberger, J. Kuhle and A. Regeniter et al., 2010. CSF-tau and CSF-Aβ1-42 in posterior cortical atrophy. Dementia Geriatric Cognitive Disorders, 29: 530-533.
    CrossRef  |  Direct Link  |  

  37. Guerreiro, N., M. Staufenbiel and B. Gomez-Mancilla, 2008. Proteomic 2-D DIGE profiling of APP23 transgenic mice brain from pre-plaque and plaque phenotypes. J. Alzheimer's Dis., 13: 17-30.
    CrossRef  |  Direct Link  |  

  38. Gasparini, F., G. Bilbe, B. Gomez-Mancilla and W. Spooren, 2008. mGluR5 antagonists: Discovery, characterization and drug development. Curr. Opin. Drug Discovery Dev., 11: 655-665.
    Direct Link  |  

  39. Guerreiro, N., B. Gomez-Mancilla and S. Charmont, 2006. Optimization and evaluation of surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry for protein profiling of cerebrospinal fluid. Proteome Sci., Vol. 4. 10.1186/1477-5956-4-7.
    CrossRef  |  

  40. Gomez-Mancilla, B., E. Marrer, J. Kehren, A. Kinnunen and G. Imbert et al., 2005. Central nervous system drug development: An integrative biomarker approach toward individualized medicine. NeuroRx, 2: 683-695.
    CrossRef  |  Direct Link  |  

  41. Lesko, L.J., R.A. Salerno, B.B. Spear, D.C. Anderson and T. Anderson et al., 2003. Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: Report of the first FDA‐PWG‐PhRMA‐DruSafe Workshop. J. Clin. Pharmacol., 43: 342-358.
    CrossRef  |  Direct Link  |  

  42. Rothermich, E.A., M.I. Brod, W.H. Schonfeld, C.R. Rowland and B. Gomez-Mancilla, 2002. Prospective study designs in outcomes research. Pharmacoeconomics, 20: 715-725.
    CrossRef  |  Direct Link  |  

  43. Anderson, D.C., B. Gomez-Mancilla, B.B. Spear, D.M. Barnes and K. Cheeseman et al., 2002. Elements of informed consent for pharmacogenetic research; perspective of the pharmacogenetics working group. Pharm. J., 2: 284-292.

  44. Spierings, E.L., B. Gomez-Mancilla, D.E. Grosz, C.R. Rowland, F.S. Whaley and K.J. Jirgens, 2001. Oral almotriptan vs oral sumatriptan in the abortive treatment of migraine: A double-blind, randomized, parallel-group, optimum-dose comparison. Arch. Neurol., 58: 944-950.
    CrossRef  |  Direct Link  |  

  45. Gomez-Mancilla, B., N.R. Cutler, M.T. Leibowitz, E.L.H. Spierings and J.A. Klapper, 2001. Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine. Cephalalgia, 21: 727-732.
    CrossRef  |  

  46. Colman, S.S., M.I. Brod, A. Krishnamurthy, C.R. Rowland, K.J. Jirgens and B. Gomez-Mancilla, 2001. Treatment satisfaction, functional status and health-related quality of life of migraine patients treated with almotriptan or sumatriptan. Clin. Therapeutics, 23: 127-145.
    CrossRef  |  Direct Link  |  

  47. Romach, M.K., E.M. Sellers, H.L. Kaplan, G.R. Somer and B. Gomez‐Mancilla, 2000. Efficacy of dexfenfluramine in the treatment of alcohol dependence. Alcoholism: Clin. Exp. Res., 24: 1534-1541.
    CrossRef  |  Direct Link  |  

  48. Busto, U.E., H.L. Kaplan, C.E. Wright, B. Gomez-Mancilla, L. Zawertailo, D.J. Greenblatt and E.M. Sellers, 2000. A comparative pharmacokinetic and dynamic evaluation of alprazolam sustained-release, bromazepam and lorazepam. J. Clin. Psychopharmacol., 20: 628-635.
    Direct Link  |  

  49. Montplaisir, J., A. Nicolas, R. Denesle and B. Gomez-Mancilla, 1999. Restless legs syndrome improved by pramipexole A double-blind randomized trial. Neurology, 52: 938-938.
    CrossRef  |  Direct Link  |  

  50. Fleishaker, J.C., L.K. Pearson, D.W. Knuth, B. Gomez-Mancilla and S.F. Francom et al., 1999. Pharmacokinetics and tolerability of a novel 5-HT1D agonist, PNU-142633F. Int. J. Clin. Pharmacol. Ther., 37: 487-492.
    Direct Link  |  

  51. Bedard, P.J., P.J. Blanchet, D. Levesque, J.J. Soghomonian and R. Grondin et al., 1999. Pathophysiology of L-dopa-induced dyskinesias. Movement Disorders, 14: 4-8.

  52. Gagnon, C., B. Gomez-Mancilla, R. Markstein, P.J. Bedard and T. Di Paolo, 1995. Effect of adding the D-1 agonist CY 208–243 to chronic bromocriptine treatment of MPTP-monkeys: Regional changes of brain dopamine receptors. Progr. Neuro-Psychopharmacol. Biol. Psychiatry, 19: 667-676.
    CrossRef  |  Direct Link  |  

  53. Blanchet, P.J., B. Gomez‐Mancilla, T. Paolo and P.J. Bedard, 1995. Is striatal dopaminergic receptor imbalance responsible for levodopa‐induced dyskinesia? Fundamental Clin. Pharmacol., 9: 434-442.
    CrossRef  |  Direct Link  |  

  54. Blanchet, P.J., B. Gomez-Mancilla and P.J. Bedard, 1994. DOPA-induced peak dose dyskinesia: Clues implicating D2 receptor-mediated mechanisms using dopaminergic agonists in MPTP monkeys. J. Neural Trans. Suppl., 45: 103-112.
    Direct Link  |  

  55. Gomez‐Mancilla, B., R. Boucher, C. Gagnon, T. Di Paolo, R. Markstein and P.J. Bedard, 1993. Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors. Movement Disorders, 8: 144-150.
    CrossRef  |  Direct Link  |  

  56. Gomez-Mancilla, B. and P.J. Bedard, 1993. Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. Clin. Neuropharmacol., 16: 418-427.
    Direct Link  |  

  57. Gagnon, C., B. Gomez-Mancilla, P.J. Bedard and T. Di Paolo, 1993. Chronic CY 208–243 treatment of MPTP-monkeys causes regional changes of dopamine and GABAa receptors. Neurosci. Lett., 163: 31-35.
    CrossRef  |  Direct Link  |  

  58. Bedard, P.J., B. Gomez-Mancilla, P. Blanchette, C. Gagnon, P. Falardeau and T. DiPaolo, 1993. Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys. Adv. Neurol., 60: 113-118.

  59. Pourcher, E., B. Gomez‐Mancilla and P.J. Bedard, 1992. Ethosuximide and tremor in Parkinson's disease: A pilot study. Movement Disorders, 7: 132-136.
    CrossRef  |  Direct Link  |  

  60. Gomez‐Mancilla, B., R. Boucher and P.J. Bedard, 1992. Effect of LY 171555 and CY 208‐243 on tremor suppression in the MPTP monkey model of parkinsonism. Movement Disorders, 7: 43-47.
    CrossRef  |  Direct Link  |  

  61. Gomez‐Mancilla, B., J.F. Latulippe, R. Boucher and P.J. Bedard, 1992. Effect of ethosuximide on rest tremor in the MPTP monkey model. Movement Disorders, 7: 137-141.
    CrossRef  |  Direct Link  |  

  62. Gomez-Mancilla, B. and P.J. Bedard, 1992. Effect of estrogen and progesterone on L-dopa induced dyskinesia in MPTP-treated monkeys. Neurosci. Lett., 135: 129-132.
    CrossRef  |  Direct Link  |  

  63. Gomez-Mancilla, B. and P.J. Bedard, 1992. Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys. Exp. Neurol., 117: 185-188.
    CrossRef  |  Direct Link  |  

  64. Gomez-Mancilla, B., R. Boucher and P.J. Bedard, 1991. Effect of clonidine and atropine on rest tremor in the MPTP monkey model of parkinsonism. Clin. Neuropharmacol., 14: 359-366.

  65. Gomez-Mancilla, B. and P.J. Bedard, 1991. Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-treated monkeys. J. Pharmacol. Exp. Therapeutics, 259: 409-413.
    Direct Link  |  
Member since November, 2017